Gene editing for hepatitis b: researchers track Long-Term safety
NCT ID NCT07254208
First seen Dec 08, 2025 · Last updated May 22, 2026 · Updated 17 times
Summary
This study is for people who have already received at least one dose of PBGENE-HBV, an experimental gene editing treatment for chronic hepatitis B. The main goal is to watch for any delayed side effects over time. About 45 participants will be followed to better understand the long-term safety of this approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ICS ARENSIA Exploratory Medicine SRL
Chisinau, Moldova, 2025, Moldova
-
Massachusetts General Hospital/Harvard University
Boston, Massachusetts, 02114, United States
-
New Zealand Clinical Research
Auckland, New Zealand, 1010, New Zealand
-
Queen Mary Hospital, University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.